Idexx Laboratories

BTIG raised the firm’s price target on Idexx Laboratories (IDXX) to $785 from $545 and keeps a Buy rating on the shares after its Q2 earnings beat. The firm is impressed by the 15%+ Y/Y reported growth in core consumables, which is the largest reported growth figure on record since 2021, the analyst tells investors in a research note. There may be further upside to numbers if the vet macro improves, coupled with the potential for greater-than-expected contribution from the recently launched products, the firm added.